Gilead Defends Remdesivir’s Efficacy In Treating COVID-19 Patients, Announces 3rd Quarter Earnings Up 17%; Science Magazine Examines U.S. Approval Of Drug, E.U. Deal To Purchase Therapeutic
CNBC: Gilead’s revenue rises 17% driven by sales of coronavirus treatment remdesivir
“Gilead Sciences reported stronger-than-expected third-quarter earnings on Wednesday as sales of its coronavirus treatment remdesivir touted by President Donald Trump drove revenue up by 17% from last year…” (Higgins-Dunn/Lovelace, 10/28).
Financial Times: Gilead insists remdesivir improves Covid-19 survival rates
“Gilead criticized a World Health Organization study that raised doubts about its Covid-19 treatment, insisting that the overnight blockbuster drug does improve survival rates for a large group of hospitalized patients…” (Kuchler, 10/28).
Science: The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug
“…On 8 October, the company inked an agreement to supply the European Union with its drug remdesivir as a treatment for COVID-19 — a deal potentially worth more than $1 billion. Two weeks later, on 22 October, the U.S. Food and Drug Administration (FDA) approved remdesivir for use against the pandemic coronavirus SARS-CoV-2 in the United States — the first drug to receive that status. The E.U. and U.S. decisions pave the way for Gilead’s drug into two major markets, both with soaring COVID-19 cases. But both decisions baffled scientists who have closely watched the clinical trials of remdesivir unfold over the past 6 months — and who have many questions about remdesivir’s worth. … Science has learned that both FDA’s decision and the E.U. deal came about under unusual circumstances that gave the company important advantages…” (Cohen/Kupferschmidt, 10/27).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.